BioSpace News Archive

Genetown

Biogen Acquires Alzheimer’s and Parkinson’s Asset from Pfizer in $710 Million Deal

Biogen is buying a novel CNS-penetrate inhibitor of casein kinase 1 (CK1) from Pfizer to develop for patients with behavioral and neurological symptoms in various psychiatric and neurologic diseases.

January 13, 2020
·
2 min read
·
Mark Terry
Deals

M&A for 2019 was Big; Will 2020 Be Even Bigger?

Consulting firm EY released its annual report on mergers and acquisitions (M&A) to coincide with the JP Morgan Healthcare conference this week. For 2019, EY indicates there were $357 billion in life science deals, an “all-time record,” surpassing the previous high in 2014.

January 13, 2020
·
4 min read
·
Mark Terry
Job Trends

J&J, RoosterBio and Element Kick Off 2020 with Expansions

The start of 2020 has also brought the need for some companies in the pharma industry to acquire the next size up in building space as they expand their employee headcount.

January 13, 2020
·
2 min read
·
Alex Keown
Drug Development

AstraZeneca and Acasti’s Fish Oil Products Flunk Trials, Leaving Amarin on Top

AstraZeneca announced that after a recommendation from an independent Data Monitoring Committee, it was abandoning its Phase III STRENGTH trial for Epanova (omega-3 carboxylic acids) for mixed dyslipidemia (MDL).

January 13, 2020
·
3 min read
·
Mark Terry
Policy

Pharmacovigilance and Regulatory Trends: An Interview with IQVIA’s Joe Rymsza

Joe Rymsza, vice president of Pharmacovigilance and Regulatory Technology Solutions for IQVIA, took time out to discuss trends in PV and regulation in the biopharma industry in the coming year.

January 13, 2020
·
6 min read
·
Mark Terry
Drug Development

Companies Provide Business and Pipeline Updates at J.P. Morgan 2020

With the J.P. Morgan Healthcare Conference in full swing, companies did not waste time in announcing deals and providing updates to their pipelines. BioSpace takes a look at some of the announcements made on day one of the annual conference in the Bay Area.

January 13, 2020
·
4 min read
·
Alex Keown
Business

Tyra Biosciences Raises $50 Million to Focus on Cancer Drug Resistance

Tyra Biosciences, based in Carlsbad, California, closed on a Series A financing worth $50 million.

January 13, 2020
·
2 min read
·
Mark Terry
Business

Genetown Startup Launches with $200 Million and Mission to Develop Affordable Drugs

With a massive $200 million Series A financing round, EQRx launches with the mission of creating novel medicines that are more affordable for patients and more sustainable for healthcare systems.

January 13, 2020
·
3 min read
·
Alex Keown
Business

On Heels of the Sale of Five Vants, Roivant Launches New Company Lokavant

Roivant Sciences, helmed by biotech billionaire Vivek Ramaswamy, launched a new subsidiary, Lokavant, a technology company with the important mission of ensuring that no clinical trial fails due to operational error.

January 13, 2020
·
2 min read
·
Alex Keown
Business

Incyte and MorphoSys Ink $1.1 Billion Immuno-Oncology Pact

MorphoSys AG and Incyte Corporation have inked a collaboration and license deal to further develop and commercialize MorphoSys’ anti-CD19 antibody tafasitamab around the world.

January 13, 2020
·
2 min read
·
Mark Terry